MILANO VINCENT 4

What Happened

• Vincent Milano, a director of Aclaris Therapeutics (ACRS), received equity awards and completed a derivative exercise. On June 4, 2026 Milano was granted two restricted stock unit (RSU) awards totaling 53,337 RSUs (42,350 and 10,987 RSUs) reported at $0.00 (derivative awards). On June 5, 2026 the filing reports an exercise/conversion of 11,580 derivative securities; those 11,580 shares were recorded as immediately disposed (reported at $0.00 in the filing).

Key Details

• Transaction dates: RSU grants recorded 2026-06-04; exercise/conversion and disposition recorded 2026-06-05. Filing date: 2026-06-08.
• Prices/values reported: Grants shown at $0.00 (derivative awards). Exercise/disposition reported at $0.00 in the filing (no cash amount reported).
• Shares owned after the transactions: Not specified in the filing.
• Notable footnotes from the filing:
  • F1: Each RSU represents a contingent right to one share of common stock.
  • F3: The 6/4 grant was made under the issuer’s non-employee director compensation policy.
  • F4: The 42,350-RSU award vests in one installment on June 4, 2027, subject to continued service.
  • F5: The shares underlying one RSU award (10,987) vested on June 5, 2026.
  • F2 references an option vesting schedule (12 monthly installments beginning July 4, 2026) tied to another award in the filing.
• Timeliness: Filing appears timely (transactions in early June, Form 4 filed June 8, 2026).

Context

• The filing shows both award grants (RSUs) and a derivative exercise/conversion with an immediate disposition of the resulting shares. Immediate disposition of exercised shares is commonly reported when shares are sold or transferred at or near conversion (the filing reports the disposition at $0.00). The 6/4 grants are director compensation awards and include a mix of immediate vesting (per F5) and future vesting (per F4). This filing is informational and does not by itself indicate the director’s investment sentiment.